`
`_______________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________________________
`
`LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
`Petitioners
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owner
`
`____________________
`
`PETITIONERS’ MOTION TO SEAL
`
`
`
`1 The word-for-word identical paper is filed in each proceeding identified in the
`heading. IPR2016-00089 has been joined with IPR2015-01097; IPR2016-00091
`has been joined with IPR2015-01100; and IPR2016-00090 has been joined with
`IPR2015-01105. Each of these joined proceedings includes Petitioners
`InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., Mylan
`Pharmaceuticals Inc., and Mylan Inc. (collectively, “InnoPharma”) in addition to
`the parties identified above.
`
`
`
`
`
`IPR2015-01097 (US Patent No. 8,751,131)
`IPR2015-01099 (US Patent No. 8,669,290)
`IPR2015-01100 (US Patent No. 8,927,606)
`IPR2015-01105 (US Patent No. 8,871,813)1
`____________________
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.55 and the Protective Orders entered
`
`in these proceedings, Petitioners hereby move to seal the following categories of
`
`exhibits:
`
`(1) deposition transcripts designated by Patent Owner as containing confidential
`
`information under the Proposed Stipulated Protective Orders (Paper 29 in
`
`IPR2015-01097; Paper 25 in IPR2015-01099; Paper 29 in IPR2015-01100;
`
`and Paper 29 in IPR2015-01105) (“Proposed Stipulated Protective Orders”);
`
`(2) documents from a concurrent district court proceeding before the United
`
`States District Court for the District of New Jersey in Senju et al. v. Lupin et
`
`al., C.A. 14:-cv-00667 (D.N.J.) (ECF No. 34) and corresponding cases
`
`designated by Patent Owner as Confidential pursuant to the Discovery
`
`Confidentiality Order (see also Senju et al. v. InnoPharma et al., C.A. No.
`
`1:14-cv-06893-JBS-KMW; ECF No. 28) (“Discovery Confidentiality
`
`Order”); and
`
`(3) Petitioners’ Replies, the Declaration of Ivan Hoffmann, and the Declaration
`
`of Dr. Jayne Lawrence filed concurrently herewith in IPR2015-01097;
`
`IPR2015-01099; IPR2015-01100; and IPR2015-01105, which contain or
`
`refer to information contained in the aforementioned transcripts designated
`
`confidential by the Patent Owner, documents designated as Protective Order
`
`Material Confidential under the Proposed Stipulated Protective Order by the
`
`2
`
`
`
`Patent Owner, documents designated as Confidential under the Discovery
`
`Confidentiality Order by the Patent Owner, or testimony designated as
`
`Protective Order Material - Fed. R. Evid. 615 under the Proposed Stipulated
`
`Protective Order by the Patent Owner.
`
`The record of an inter partes review proceeding, including documents and
`
`things, is made available to the public, except as otherwise ordered. 37 C.F.R. §
`
`42.14. Despite the default rule of public availability, the Board will seal
`
`confidential information for “good cause,” because it is necessary to “strike a
`
`balance between the public’s interest in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`It is Petitioners’ understanding that information in the following documents
`
`has been designated as confidential to Patent Owner, pursuant to the Proposed
`
`Stipulated Protective Order:
`
` Portions of EX1125 (Myers Transcript), 141:9-203:10.
`
` Portions of EX1123 (Paulson Transcript), 71:13-74:11, 105:13-106:13,
`
`107:4-11, 108:19-109:4, 109:11-16, 113:1-7, 113:16-116:22, 118:7-123:14,
`
`124:11-22, 125:5-6, 125:12-20, 126:2-8, 126:12-22, 127:6-128:3, 128:17-19,
`
`131:5-132:6, 132:9, 132:12-133:21, 134:8-135:1, 137-142:12, 143:21-144:1,
`
`144:7-22, 145:14-146:7, 146:13-15, 146:19-147:9, 147:15-22, 148:12-18,
`
`3
`
`
`
`149:3-7, 149:12-14, 149:17-151:19, 152:15-153:4, 156:10-157:12, 159:7-
`
`160:9, 170:19-172:7, 180:9-12, 181:13-19, 182:6-183:9, 183:19-184:19,
`
`187:13-188:15, 191:16-312:10.
`
` Portions of EX1120 (Trattler Transcript), 111:10-12.
`
` Portions of EX1099 (Williams Transcript), 121:5-18, 122:7-20, 123:1-
`
`125:16, 126:4-127:2.
`
` Portions of EX1121 (Jarosz Transcript), 8:17-18, 9:5-8, 97:5-98:16, 107:7-
`
`111:11.
`
` Portions of EX1122 (Hofmann Declaration)
`
` Portions of EX1094 (Lawrence Declaration)
`
` Portions of Petitioner’s Reply to Patent Owner’s Response
`
` The entirety of EX1104, EX1133, EX1149, EX1154, and EX1158
`
`Patent Owner has requested that Petitioners file these documents under seal
`
`and file an appropriate motion to seal under the Proposed Stipulated Protective
`
`Order. (See Appendix A attached hereto). Petitioners have no independent basis for
`
`the aforementioned documents to be sealed and thus make no assertion as to
`
`whether or not they contain confidential information. Patent owner does not
`
`4
`
`oppose this motion.
`
`
`
`
`
`
`April 22, 2016
`
`
`
`
`
`Respectfully submitted,
`
`
`
` /Deborah Yellin/
`Deborah H. Yellin
`Reg. No. 45,904
`CROWELL & MORING LLP
`Intellectual Property Group
`P.O. Box 14300
`Washington, DC 20044-4300
`
`5
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that the foregoing document entitled
`
`PETITIONERS’ MOTION TO SEAL was served electronically via email on April
`
`22, 2016 to Patent Owner’s counsel of record and counsel of record for Petitioners
`
`InnoPharma at the following:
`
`Patent Owner
`
`Bryan.Diner@finnegan.com
`
`Justin.Hasford@finnegan.com
`
`Joshua.Goldberg@finnegan.com
`
`Petitioners InnoPharma
`
`Jitty.malik@alston.com
`
`James.abe@alston.com
`
`Lance.soderstrom@alston.com
`
`
`
`Respectfully submitted,
`
`
`
` /Shannon M. Lentz/
`Shannon M. Lentz
`Reg. No. 65,382
`CROWELL & MORING LLP
`Intellectual Property Group
`P.O. Box 14300
`Washington, DC 20044-4300
`
`6
`
`
`April 22, 2016
`
`
`
`
`
`
`
`Appendix A
`Appendix A
`
`
`
`
`
`
`
`IPR2015-01097
`IPR2015-01097
`IPR2015-01099
`IPR2015-01099
`IPR2015-01100
`IPR2015-01100
`IPR2015-01105
`IPR2015-01105
`
`
`
`Lentz, Shannon
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Ferrill, Elizabeth <Elizabeth.Ferrill@finnegan.com>
`Thursday, April 21, 2016 1:18 PM
`Yellin, Deborah
`Lentz, Shannon; Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi; Diner, Bryan; Hasford,
`Justin; Fujiwara, Chiaki; Lebeis, Jessica; Goldberg, Joshua; Malik, Jitty; Abe, James
`RE: IPR2015-01097, -01099, -1100, and -1105
`
`Hi Debbie,
`
`Senju confirms that neither the deposition transcript of Mr. Jarosz from March 16 nor the deposition transcript of Mr.
`Sawa from March 18 contains confidential information.
`
`On a related note, as agreed in the parties' Joint Stipulation entered on January 28, after filing your reply tomorrow,
`please promptly advise Senju when all Lupin's declarants are available for cross‐examination during the period of April
`27 and May 6.
`
`Best,
`Beth
`
`
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com | www.finnegan.com
`
`
`
`‐‐‐‐‐Original Message‐‐‐‐‐
`From: Yellin, Deborah [mailto:DYellin@crowell.com]
`Sent: Wednesday, April 20, 2016 11:06 PM
`To: Ferrill, Elizabeth
`Cc: Lentz, Shannon; Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi; Diner, Bryan; Hasford, Justin; Fujiwara, Chiaki;
`Lebeis, Jessica; Goldberg, Joshua; Malik, Jitty; Abe, James
`Subject: Re: IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Thank you Beth.
`In addition, please confirm that you do not consider March 16 and March 18 deposition transcripts of Mr. Jarosz or Mr.
`Sawa to be confidential and will not be providing redacted versions. If we do not hear from you in this regard we will
`not consider them confidential.
`
`Best
`Debbie
`
`Sent from my iPhone
`
`On Apr 20, 2016, at 8:45 PM, Ferrill, Elizabeth
`<Elizabeth.Ferrill@finnegan.com<mailto:Elizabeth.Ferrill@finnegan.com>> wrote:
`
`
`1
`
`
`
`Debbie,
`
`Thank you for your email. Senju does not object to Lupin filing InnoPharma's Exhibits 1117, 1134, 1140, and 1152,
`provided that Lupin files the appropriate Motion to Seal. Moreover, as agreed on March 15, 2016, Senju does not object
`to Lupin filing the depositions transcripts from the related district court litigations as well as the ‐00902 and ‐00903
`proceedings, provided that Lupin mirrors the redactions made by InnoPharma and provided that Lupin files the
`appropriate Motion to Seal.
`
`Best regards,
`Beth
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image001.jpg>
`
`
`
`From: Yellin, Deborah [mailto:DYellin@crowell.com]
`Sent: Tuesday, April 19, 2016 4:24 PM
`To: Ferrill, Elizabeth
`Cc: Lentz, Shannon; Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi; Diner, Bryan; Hasford, Justin; Fujiwara, Chiaki;
`Lebeis, Jessica; Goldberg, Joshua; Malik, Jitty; Abe, James
`Subject: IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Counsel:
`
`Pursuant to 35 U.S.C. 316(a)(1) and 37 CFR 41.157(e)(7), Lupin will be filing the deposition transcripts of Patent Owner's
`witnesses. Per Senju's agreement of March 15, 2016, Lupin intends to file the deposition transcripts from the related
`district court litigation as well as the 2015‐00902 and ‐00903 IPRs. For Mr. Sawa, Lupin will not cite to or file his district
`court deposition.
`
`Lupin intends to mirror the redactions from the InnoPharma filing in its filing on Friday, April 22, 2016.
`
`In addition, Lupin does not believe that Counsel for Patent Owner has designated the March 16, 2016 deposition of Mr.
`Sawa, or the March 18, 2016 deposition of Mr. Jarosz as confidential. If Counsel for Patent Owner disagrees with this
`understanding, we request that you please provide us with redacted versions of these transcripts by April 21, 2016 so
`that we may file them publicly on April 22, 2016.
`
`Lastly, like InnoPharma, Lupin seeks Senju's permission to file the following confidential documents in connection with
`its filing on Friday, April 22, 2016:
` InnoPharma EX1117
` InnoPharma EX1134
` InnoPharma EX1140
` InnoPharma EX1152.
`
`
`2
`
`
`
`These documents will be cited as part of the Hofmann declaration, and Mr. Hofmann is already aware of the content of
`these documents through the corresponding IPRs2015‐00902 and 00903 as well as the district court litigation. We are
`amenable to file the documents under the "confidential" designation pursuant to the IPR protective order, similar to
`their use in IPR2015‐00902 and 903. Please let us know if Senju will consent to Lupin's request.
`
`Please let us know if you have any questions.
`Best
`Debbie and Jonathan
`
`
`
`From: Lebeis, Jessica [mailto:Jessica.Lebeis@finnegan.com]
`Sent: Tuesday, March 15, 2016 8:15 PM
`To: Yellin, Deborah; Ferrill, Elizabeth
`Cc: Lindsay, Jonathan; Suzuki, Chiemi; lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Fujiwara, Chiaki; Goldberg,
`Joshua; Lentz, Shannon; Galluzzo, Vince; Malik, Jitty
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Debbie,
`
`Senju will not oppose Petitioners relying on and citing to the district court deposition transcripts, and transcripts from
`the depositions in the 2015‐00902 and ‐00903 IPRs, in preparing Petitioner's Reply, for Dr. Williams, Dr. Trattler, Dr.
`Myers, Dr. Paulson, Dr. Davies, and Mr. Jarosz, so long as Petitioners mark these transcripts and any IPR2015‐01097, ‐
`01099, ‐01100, and ‐01105 transcripts, if appropriate, as confidential under the protective order in IPR2015‐01097, ‐
`01099, ‐01100, and ‐01105 if filing as exhibits.
`
`With respect to Mr. Sawa, Senju will not oppose Petitioners relying on and citing to Mr. Sawa's transcript from his
`deposition in the 2015‐00902 and ‐00903 IPRs, so long as Petitioners mark this transcript and Mr. Sawa's IPR2015‐
`01097, ‐01099, ‐01100, and ‐01105 transcript, if appropriate, as confidential under the protective order in IPR2015‐
`01097, ‐01099, ‐01100, and ‐01105, if filing as an exhibit. Senju cannot agree to Petitioners relying on and citing to Mr.
`Sawa's district court deposition transcript, which is not final and the subject of a privilege dispute that Lupin and
`InnoPharma have raised.
`
`Senju agrees that Petitioners may apply the testimony from these transcripts in the IPRs relating to the '131, '813, and
`'606 patents.
`
`Please let us know as soon as possible which declarants you will not depose, so that we may promptly inform them.
`
`Best regards,
`
`Jessica
`
`From: Yellin, Deborah [mailto:DYellin@crowell.com]
`Sent: Tuesday, March 15, 2016 5:34 PM
`To: Ferrill, Elizabeth
`Cc: Lindsay, Jonathan; Suzuki, Chiemi; lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua; Lentz, Shannon; Galluzzo, Vince; Malik, Jitty
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`3
`
`
`
`
`Justin and Jessica,
`
`Further to our discussion of last week at Dr. William's deposition, we are reaching out to confirm that Senju will not
`oppose following:
`
`That we may rely on and cite to the district court deposition transcripts, and transcripts from the depositions in the
`2015‐00902 and ‐00903 IPRs, in preparing Petitioner's Reply, for Senju's seven declarants, namely Dr. Williams, Dr.
`Trattler, Dr. Myers, Dr. Paulson, Dr. Davies, Mr. Sawa, and Mr. Jarosz. To this end, Senju would agree that we may
`apply the testimony from these transcripts in the IPRs relating to the '131, '813, and '606 patents.
`
`If you are amenable to the above, we may agree not to take some of the depositions of your declarants.
`
`Best
`Debbie
`
`From: Ferrill, Elizabeth [mailto:Elizabeth.Ferrill@finnegan.com]
`Sent: Friday, March 11, 2016 1:04 PM
`To: Yellin, Deborah; jitty.malik@alston.com<mailto:jitty.malik@alston.com>
`Cc: Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua; Lentz, Shannon; Galluzzo, Vince
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Debbie,
`
`Thank you for your email. We are confirmed for the Davies, Trattler, Paulson, and Myers depositions on the dates
`indicated below. We can confirm that none of these depositions will need to start before 9 am.
`
`As for Dr. Williams, he is only available on Wednesday, March 30.
`
`Best,
`Beth
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image004.jpg>
`
`
`
`
`
`From: Yellin, Deborah [mailto:DYellin@crowell.com]
`Sent: Friday, March 11, 2016 10:29 AM
`To: Ferrill, Elizabeth; jitty.malik@alston.com<mailto:jitty.malik@alston.com>
`
`4
`
`
`
`Cc: Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua; Lentz, Shannon; Galluzzo, Vince
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Hi Beth,
`
`The following deposition dates you suggested are acceptable for us:
`
` *
`
` Dr. Davies: Monday, March 21, 2016 at Finnegan's Washington, DC office
`
` *
`
` *
`
` Dr. Trattler: Monday, March 21, 2016, in Miami, Florida
`
` Dr. Paulson: Tuesday, March 22, 2016, at Finnegan's Washington, DC office
`
` Dr. Myers: Thursday, March 24, 2016 at Finnegan's Washington, DC office
`
` *
`
`
`
`Please let us know if you require any earlier start times than 9 am.
`
`
`
`With regard to Dr. Williams, would he be available on Thursday March 31 or Friday April 1 in Austin, TX?
`
`
`
`Best
`
`Debbie
`
`
`
`From: Ferrill, Elizabeth [mailto:Elizabeth.Ferrill@finnegan.com]
`Sent: Tuesday, March 08, 2016 4:15 PM
`To: Yellin, Deborah; jitty.malik@alston.com<mailto:jitty.malik@alston.com>
`Cc: Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua; Lentz, Shannon
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Hi Debbie,
`
`Starting at 9 a.m. for the Jarosz and Sawa depositions will work for us.
`
`Best,
`Beth
`
`
`5
`
`
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image004.jpg>
`
`From: Yellin, Deborah [mailto:DYellin@crowell.com]
`Sent: Tuesday, March 8, 2016 2:23 PM
`To: Ferrill, Elizabeth; jitty.malik@alston.com<mailto:jitty.malik@alston.com>
`Cc: Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua; Lentz, Shannon
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`
`
`
`
`IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Dear Beth,
`
`Thank you. March 16, 2016 for Mr. Jarosz and March 18, 2016 for Mr. Sawa work for us. We will notice them for 9 am
`at your Washington, DC office, unless you would like to request an earlier start time. With regard to the other
`witnesses, we should be able to revert back to you shortly.
`
`Best
`Debbie
`
`
`
`From: Ferrill, Elizabeth [mailto:Elizabeth.Ferrill@finnegan.com]
`Sent: Monday, March 07, 2016 11:42 AM
`To: jitty.malik@alston.com<mailto:jitty.malik@alston.com>; Yellin, Deborah
`Cc: Lindsay, Jonathan; Rea, Teresa; Suzuki, Chiemi;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Counsel,
`
`As a follow up to my previous messages, Mr. Sawa is available for his IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`deposition on Friday, March 18, 2016 at Finnegan's Washington, DC office.
`
`Best regards,
`Beth
`
`
`6
`
`
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image004.jpg>
`
`From: Ferrill, Elizabeth
`Sent: Friday, March 4, 2016 10:11 AM
`To: jitty.malik@alston.com<mailto:jitty.malik@alston.com>; dyellin@crowell.com<mailto:dyellin@crowell.com>
`Cc: jlindsay@crowell.com<mailto:jlindsay@crowell.com>; trea@crowell.com<mailto:trea@crowell.com>;
`csuzuki@crowell.com<mailto:csuzuki@crowell.com>;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua
`Subject: RE: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Counsel,
`
`As a follow up to my previous message, Dr. Davies is available for his IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`deposition on Monday, March 21, 2016 at Finnegan's Washington, DC office.
`
`We will let you know about Mr. Sawa's availability soon.
`
`Best regards,
`Beth
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image004.jpg>
`
`
`
`
`
`From: Ferrill, Elizabeth
`Sent: Wednesday, March 2, 2016 6:18 PM
`To: jitty.malik@alston.com<mailto:jitty.malik@alston.com>; dyellin@crowell.com<mailto:dyellin@crowell.com>
`Cc: jlindsay@crowell.com<mailto:jlindsay@crowell.com>; trea@crowell.com<mailto:trea@crowell.com>;
`csuzuki@crowell.com<mailto:csuzuki@crowell.com>;
`lance.soderstrom@alston.com<mailto:lance.soderstrom@alston.com>;
`james.abe@alston.com<mailto:james.abe@alston.com>; Diner, Bryan; Hasford, Justin; Lebeis, Jessica; Fujiwara, Chiaki;
`Goldberg, Joshua
`Subject: Deposition Availability ‐ IPR2015‐01097, ‐01099, ‐1100, and ‐1105
`
`Counsel,
`
`
`7
`
`
`
`Patent Owner's witnesses are available for their IPR2015‐01097, ‐01099, ‐1100, and ‐1105 depositions on the following
`days:
`
` *
`
` Mr. Jarosz: Wednesday, March 16, 2016 at Finnegan's Washington, DC office
`
` Dr. Trattler: Monday, March 21, 2016, in Miami, Florida
`
` Dr. Paulson: Tuesday, March 22, 2016, at Finnegan's Washington, DC office
`
` *
`
` *
`
` Dr. Myers: Thursday, March 24, at Finnegan's Washington, DC office
`
` *
`
` *
`
` Dr. Williams: Wednesday March 30, 2016, in Austin, Texas
`
`
`We will let you know about Dr. Davies' and Mr. Sawa's availability soon.
`
`Best regards,
`
`Beth
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001‐4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com<mailto:elizabeth.ferrill@finnegan.com> |
`www.finnegan.com<http://www.finnegan.com/>
`________________________________
`<image004.jpg>
`
`
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`
`
`8
`
`
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`This e‐mail message is intended only for individual(s) to whom it is addressed and may contain information that is
`privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have
`received this message in error, please advise the sender by return e‐mail and delete it from your mailbox. Thank you.
`
`
`
`
`9